Erik van Werkhoven

Erik van Werkhoven is an active Researcher in the Department of Hematology at Erasmus University Medical Center, with a robust publication record focusing on clinical oncology. His work spans breast cancer, radiation therapy, and systemic treatments, evidenced by 78 research outputs including recent high-impact publications in 2025.

His research interests center on Oncology with specialized expertise in Breast Cancer Research, Radiation Therapy, and Chemotherapy. Key focus areas include neoplasm treatment outcomes, cosmetic and quality-of-life impacts post-therapy, and innovative clinical trial designs for rare cancers. His fingerprint analysis shows dominant activity in Neoplasm (100%), Breast Cancer (97%), and Chemotherapy (95%) research.

Recent publications demonstrate strong trends in multicenter clinical trials (e.g., STRONG II trial for cholangiocarcinoma) and longitudinal studies assessing cognitive outcomes in glioma patients. His work frequently appears in top journals like Radiotherapy and Oncology and European Journal of Cancer, with significant emphasis on treatment toxicity and survival metrics.

Collaboration patterns show extensive national and international network activity, particularly in radiation oncology consortia. His research portfolio includes substantial work on breast-conserving therapy complications, oral cavity cancer management, and rare malignancy trials, reflecting both clinical depth and methodological rigor.